Search
Ibrigampar
go.drugbank.com/drugs/DB05490InvestigationalAMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. … T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin.
Acellular nerve allograft
go.drugbank.com/drugs/DB30293ApprovedInvestigationalOur team is working on the full update, which will be available soon. [L54673,L54668] … Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral
Encainide
go.drugbank.com/drugs/DB01228ApprovedWithdrawnThe manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991. … Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack.
Synonyms: (±)-4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide, 4-Methoxy-N-{2-[2-(1-methyl-piperidin-2-yl)-ethyl]-phenyl}-benzamideAdrenomedullin
go.drugbank.com/drugs/DB19102InvestigationalAdrenomedullin is under investigation in clinical trial NCT06072118 (Adrenomedullin for CADASIL).
Categories: Compounds used in a research, industrial, or household settingFasinumab
go.drugbank.com/drugs/DB12157Investigational[A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions. … NSAIDs and/or opioids) in this patient population.[A241165] NGF was first discovered in the 1950s[A241180] and was the first neurotrophic factor to be identified and biochemically characterized.
AEOL-10150
go.drugbank.com/drugs/DB05874ExperimentalAEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Ezatiostat
go.drugbank.com/drugs/DB05460InvestigationalEzatiostat has myelostimulant activity in preclinical rodent models and human bone marrow cultures, and differentiates granulocytes and monocytes in HL60 cells. … It might also be relevant as an adjunct therapy since a reduction in blood cell levels is also a common, toxic effect of many standard chemotherapeutic drugs.
CRx-119
go.drugbank.com/drugs/DB05688ExperimentalCRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of
RTP-801i
go.drugbank.com/drugs/DB06048InvestigationalRTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801.
AGS-004
go.drugbank.com/drugs/DB05742InvestigationalNon-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do not provide antiviral protection against the … This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment.